Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 14/20 | 0.80 |
| ▸ | DRD3 | P35462 | 14/20 | 0.80 |
| ▸ | HTR1A | P08908 | 13/20 | 0.80 |
| ▸ | HTR2C | P28335 | 7/20 | 0.79 |
| ▸ | DRD2 | P14416 | 4/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.65 |
| ▸ | HRH1 | P35367 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4531568 | 0.89 | DRD3 (1.00) | HTR2ADRD3HTR1AHTR2CDRD2 | |
| SCHEMBL4522867 | 0.88 | DRD3 (1.00) | HTR2ADRD3HTR1AHTR2CDRD2 | |
| SCHEMBL4522741 | 0.87 | HTR1A (0.79) | HTR2ADRD3HTR1AHTR2CDRD2 | |
| SCHEMBL4532335 | 0.84 | DRD3 (1.00) | HTR2ADRD3HTR1AHTR2CDRD2 | |
| SCHEMBL4525601 | 0.83 | HSD17B10 (0.72) | HTR2ADRD3HTR1AHTR2CDRD2 | |
| SCHEMBL4522956 | 0.79 | DRD3 (1.00) | HTR2ADRD3HTR1AHTR2CDRD2 | |
| SCHEMBL11065784 | 0.78 | KCNH2 (0.62) | HTR2ADRD3HTR1AHTR2CDRD2 | |
| SCHEMBL4521524 | 0.77 | KCNH2 (1.00) | HTR2ADRD3HTR1AHTR2CKCNH2 | |
| SCHEMBL4525524 | 0.77 | HTR1A (1.00) | HTR2ADRD3HTR1AHTR2CDRD2 | |
| SCHEMBL4520989 | 0.76 | DRD3 (1.00) | HTR2ADRD3HTR1AHTR2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | HTR2A 2/4885DRD3 10/4885HTR1A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.